Forte Biosciences, Inc. (FBRX)
76.94
+0.02
(+0.03%)
USD |
NASDAQ |
Aug 24, 16:00
76.94
0.00 (0.00%)
After-Hours: 20:00
Forte Biosciences Total Liabilities (Quarterly) : 21.95M for June 30, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 21.95M |
| March 31, 2026 | 25.12M |
| December 31, 2025 | 21.79M |
| September 30, 2025 | 12.99M |
| June 30, 2025 | 9.17M |
| March 31, 2025 | 9.032M |
| December 31, 2024 | 9.081M |
| September 30, 2024 | 8.58M |
| June 30, 2024 | 9.117M |
| March 31, 2024 | 3.332M |
| December 31, 2023 | 3.666M |
| September 30, 2023 | 7.471M |
| June 30, 2023 | 6.30M |
| March 31, 2023 | 3.76M |
| December 31, 2022 | 3.179M |
| September 30, 2022 | 2.293M |
| June 30, 2022 | 1.513M |
| March 31, 2022 | 1.256M |
| December 31, 2021 | 1.758M |
| September 30, 2021 | 3.74M |
| June 30, 2021 | 2.978M |
| Date | Value |
|---|---|
| March 31, 2021 | 2.37M |
| December 31, 2020 | 2.259M |
| September 30, 2020 | 2.411M |
| June 30, 2020 | 3.433M |
| March 31, 2020 | 16.55M |
| December 31, 2019 | 1.912M |
| September 30, 2019 | 50.95M |
| June 30, 2019 | 48.75M |
| March 31, 2019 | 49.87M |
| December 31, 2018 | 44.94M |
| September 30, 2018 | 42.69M |
| June 30, 2018 | 41.25M |
| March 31, 2018 | 19.06M |
| December 31, 2017 | 20.99M |
| September 30, 2017 | 22.06M |
| June 30, 2017 | 22.20M |
| March 31, 2017 | 35.80M |
| December 31, 2016 | |
| September 30, 2016 | |
| June 30, 2016 | |
| March 31, 2016 | 24.97M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| argenx SE | -- |
| ACADIA Pharmaceuticals, Inc. | 436.29M |
| Alnylam Pharmaceuticals, Inc. | 4.205B |
| Anika Therapeutics, Inc. | 46.19M |
| Savara, Inc. | 48.48M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 205.74M |
| Shareholders Equity (Quarterly) | 183.79M |
| Current Ratio | 10.01 |